GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline.
GSK already owned a stake in GlycoVaxyn and had been working with the company since 2012 on the development of conjugate vaccines for bacterial infections.
Buying the remainder of the company gives it a portfolio of early-stage candidates including an Escherichia coli vaccine in phase I trials and - more importantly - exclusive rights to the Swiss company's platform technology for making new vaccine candidates.
